Store
Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028
Publication Date: November 29, 2023
Tags: Chronic Diseases, Coagulation, Diagnostic Instruments, Genetic Diseases, Liquid Biopsy, Molecular Diagnostics, Neurological Diseases, Next-Generation Sequencing (NGS), Oncology and Cancer, Personalized Medicine, Pharmaceuticals, Respiratory Diseases, Sequencing Technologies
Pages: 260
SKU: 23-702
In recent decades, genetic technologies for research and diagnostics have transformed healthcare, offering new possibilities in precision medicine and disease management. Next-generation sequencing (NGS) has revolutionized genetic disease diagnostics and oncology, providing comprehensive insights at a relatively low cost. PCR continues to evolve, remaining a central tool in molecular diagnostics. In situ hybridization techniques (ISH) like FISH are crucial for understanding gene expression and genetic alterations in situ.
Stay ahead of the competition with comprehensive market insights on genetic technologies and molecular diagnostics from Kalorama Information in Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028. Order your copy of the report to gain unparalleled knowledge on the top companies, technologies, and market trends shaping the future of healthcare.
Key Highlights:
- Cancer testing is advancing towards precision medicine, utilizing numerous biomarkers for precise diagnosis, therapy selection, and monitoring. Growth rates in cancer testing surpass other IVD fields.
- Breakthroughs in rare inherited/genetic diseases and Non-Invasive Prenatal Testing (NIPT) are transforming healthcare.
- The report covers market data for molecular testing in oncology, rare inherited/genetic diseases, and NIPT. It includes segments such as oncology assays, colon cancer molecular screens, ISH/FISH, HPV, and CTCs.
Regional Market and Forecast:
- North America leads in these areas of testing but is experiencing slightly lower growth rates compared to APAC and ROW.
- The report provides market sizing and forecasts for regions worldwide, including Asia Pacific, Europe, America, and RoW.
Table: Molecular Diagnostics in Oncology, Genetic, NIPT, Market Revenues Forecast, 2023-2028 (in millions $)
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR |
| Oncology assays (incl. CDx) |
$XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Colon cancer molecular screen | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| ISH/FISH | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| HPV | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Prenatal testing – NIPT | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Genetic/inherited disease assays |
$XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| CTCs | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Introduction
Oncology Molecular/Genetic Testing and Diagnostics
Liquid Biopsy Expanding New Possibilities
- Table 1-1: Comparison of Tissue and Liquid Biopsy
Successes in Prenatal, Newborn Testing, Rare Genetic/Inherited Diseases
Market Revenues
- Table 1-2: Molecular Diagnostics in Oncology, Genetic, NIPT, Market Revenues Forecast, 2023-2028 ($M)
- Figure 1-1: Global Genetic/Molecular Test Sales in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT, 2023-2028 ($M)
Scope and Methodology
Terminology Related to Companion Diagnostics, Precision/Personalized Medicine
- Table 1-3: Industry Recognized Terms for Companion Diagnostics and Personalized Medicine
Chapter 2: Introduction and Trends
DNA and RNA Variants
- Table 2-1: Selected Major Biomarkers in Oncology Personalized Medicine Tests
Cancer Markers in Widespread Usage
- Table 2-2: Relevant DNA/RNA Variants for Top Six Cancer Types (Breast, Colon, Gastric, Liver/Biliary, Lung, Prostate)
- Table 2-3: Relevant DNA/RNA Variants for High Incidence Cancer Types (excl. top six)
Molecular Diagnostics in Hereditary Cancer Diagnosis
- Table 2-4: Selected Companies Offering LDTs for Hereditary Risk of Cancer
Genetics of Inherited Diseases
- Table 2-5: Selected Inherited/Genetic Disorders
Thrombophilia, Coagulation
Inherited/Genetic Disease Tests in New Areas
- Table 2-6: Selected Genomic Tests for Inherited Diseases
Techniques Used in Genetic Analysis
Polymerase Chain Reaction (PCR)
- Table 2-7: Selected Companies Marketing Open PCR Platforms That Can be Used by Laboratories for LDTs
In Situ Hybridization (ISH)
- Table 2-8: Selected Advanced Histology Techniques
- Table 2-9: Selected In Situ Hybridization-based Tests
Next-Generation Sequencing (NGS)
- Table 2-10: Selected Companies Marketing Next Generation Sequencing Platforms to Clinical Laboratories
Chapter 3: Oncology Molecular Diagnostics and Genetic Testing
Introduction
- Table 3-1: Selected Molecular Tumor Marker Test Innovations
LDTs Used Across Diagnosis, Prognosis, Screening, Personalized Medicine
- Table 3-2: Selected Cancer Diagnosis/Prognosis/Personalized Medicine Test Services Based on LDTs
- Table 3-3: Selected Companies Offering LDTs for Risk of Disease – Cancer and Beyond
Companion Diagnostics
- Table 3-4: FDA Approved or Cleared Companion Diagnostic (CDx) Tests and Corresponding Therapies, Oncology
Pharmacodiagnostic Tests
Predictive Biomarker Tests for Drug-Gene Match
Histology, ISH, FISH Established
Significant Use in HPV Testing
- Table 3-5: Selected HPV Test Innovations
Liquid Biopsy
- Table 3-6: Selected Liquid Biopsy Innovations
Next Generation Sequencing
ctDNA and cfDNA Testing
- Table 3-7: Selected Liquid Biopsy Tests That Assess Multiple Analytes
- Table 3-8: Selected Liquid Biopsy Tests for Research Use Only
Colon Cancer Screening
Circulating Tumor Cells
- Table 3-9: Selected Innovations in CTC Technology
ctDNA Testing Companies and Technologies
- Table 3-10: Selected Market-Available ctDNA-based Liquid Biopsy Tests
Exosome Sequencing
- Table 3-11: Selected Exosome Test Innovations
The Future for Liquid Biopsy
AI in Liquid Biopsy
- Table 3-12: Selected AI/Liquid Biopsy Initiatives
Chapter 4: Rare Inherited/Genetic Diseases, NIPT, Newborn Testing
Introduction
Prenatal and Newborn Testing
- Table 4-1: Selected Molecular Tests for Prenatal Analysis
- Table 4-2: Selected Companies and Clinical Laboratories Offering PCR-based Tests
- Table 4-3: Selected Examples of Companies Marketing FISH Tests or Probes for Inherited Disorders
- Table 4-4: Selected Companies and Clinical Laboratories Offering Sequencing-based Tests
- Table 4-5: Selected Companies and Clinical Laboratories with Microarray-Based Tests
- Table 4-6: Selected Companies with Tests for Chromosomal Abnormalities
Non-Invasive Prenatal Testing (NIPT)
- Table 4-7: Selected Companies Developing and/or Marketing Non-Invasive Prenatal Tests
LDTs Used Across Prenatal and Genetic Disease Screening, Testing
- Table 4-8: Selected Companies/Laboratories with Genetic Tests or Screening Innovations Based on LDTs
Thrombophilia and Coagulation Markers
Chapter 5: Market Analysis and M&A Activity
Introduction
Market Revenues and Forecast
- Table 5-1: Global Genetic/Molecular Test Sales in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT, by Type, 2023-2028 ($M)
- Figure 1-1: Global Genetic/Molecular Test Sales in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT, by Type, 2023-2028 ($M)
- Table 5-2: Global Genetic/Molecular Testing in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT – Shares, by Type, 2023-2028 (%)
- Table 5-3: Global Genetic/Molecular Testing in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT – Regional Shares, 2023 & 2028 ($M) (%)
- Figure 5-2: Global Genetic/Molecular Testing in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT – Regional Shares, 2023 (%)
- Figure 5-3: Global Genetic/Molecular Testing in Oncology, Inherited/Genetic, Prenatal, Newborn, NIPT – Regional Shares, 2028 (%)
Market Drivers and Challenges
Clinical Utility Needed with Molecular Diagnostics
Slowly Emerging Practices with Rare Diseases
Incremental Nature of Technological, Medical Advances
Mergers & Acquisitions
- Table 5-4: Selected IVD Mergers and Acquisitions 2019-2023
Chapter 6: Company Profiles
Abbott
Companion Diagnostic Testing
Liquid Biopsy
Agilent Technologies
Genomics
Cytogenetic Analysis
Dako, Companion Diagnostics
Sequencing
Becton, Dickinson and Company (BD)
Cytology
BGI Genomics
Prenatal Testing
MGI
Biocept
Exact Sciences
Foundation Medicine
Guardant Health
Hologic
Panther Molecular System
Cytology
Illumina
Myriad Genetics
Natera
Neogenomics
Qiagen
Precision Medicine/Companion Diagnostics
Liquid Biopsy
Cervical Cancer Testing
Roche
Cancer Companion Testing
HPV
IT in Anatomical Pathology
Sysmex Inostics
Forging New Markets
Thermo Fisher Scientific
Next Generation Sequencing
Oncology Companion Diagnostics
Ventana Medical Systems (Roche)
Related products
Single Cell Analysis in Genomics: Next-Generation Sequencing and Other Technology, 2023-2027
April 6, 2023
Single cell RNA-seq enables new types of analyses, for instance: understanding tumour heterogeneity and clonal evolution (including studying lineage analysis, cancer stem cells, and drug-resistant and metastatic clones), understanding complex tissues (e.g. neural tissues), high resolution identification of cell types and markers, and understanding differentiation pathways in developmental and systems biology.
Explore the dynamic market…
$4,000.00 – $6,000.00
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
$3,000.00 – $4,500.00
In Vitro Diagnostics Business Outlook, 2024
December 20, 2024
In Vitro Diagnostics Business Outlook, 2024 is a must-have publication offering exclusive information and data that cannot be found elsewhere. With a focus on the in vitro diagnostics (IVD) market, this publication provides valuable insights to help businesses identify growth opportunities, understand market trends, and tailor strategies for success.
Key Features:
…
$4,995.00 – $9,995.00
